Prot #KT-US-471-0119: A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)

Project: Research project

Project Details

StatusFinished
Effective start/end date10/14/20 → 10/14/23

Funding

  • Gilead Sciences, Inc (Prot #KT-US-471-0119 // Prot #KT-US-471-0119)
  • Kite Pharma, Inc. (Prot #KT-US-471-0119 // Prot #KT-US-471-0119)